CClinicalTrials.gg
WithdrawnNCT03295175DISMUDUpdated Mar 13, 2024

Distribution of Smooth Muscle In Dartos In The Non Conspicuous Penis

An observational study in Congenital Urogenital Anomaly, sponsored by Hospital Universitario San Ignacio. Withdrawn at 1 site in Colombia. Open to male participants aged 1 Month to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-13.

Sponsored by Hospital Universitario San Ignacio · Observational

Why this study was withdrawn
The project never started and contact with the main researcher was lost.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
1 Month to 10 Years
Sex
Male
01

Study summary

Non-conspicuous penis (congenital megaprepuce, occult penis) is a symptomatic malformation that includes phimosis and excessively baggy, urine-filled prepuce with alteration of the appearance of the penis. A redundant and enlarged foreskin is the main feature of this entity.This congenital anomaly is difficult to diagnose and may have association with other pathologies such as buried penis.

Currently, part of the megaprepuce skin is used to correct the defect. A recent study shows that patients with this pathology and hypospadias present mostly defects in the muscle dartos. The investigators do not know the physiological bases of the megaprepuce, neither the clinical and aesthetics implications of this abnormal tissue for the patient, and how this affects the postoperative evolution. With the present study the investigators intended to answer these questions and to open paths for future research in this area.

Read the detailed description

After informed consent, patients will be labeled with a research record number other than the identity document or the number of the attention. The urologist who perform the correction of the megaprepuce, will take a segment of the dartos and send it for histopathological analysis: staining with hematoxylin-eosin, smooth muscle actin marker, associated with the research record number. Same procedure will be performed with the controls and hypospadias group. Only the principal investigator will know the assignment of medical record and their respective group (congenital megaprepuce, hypospadias or controls). The samples will be sent to pathology without any clinical data, and they will be analyzed by two pathologists, both blind.

02

Conditions studied

  • Congenital Urogenital Anomaly

Keywords

  • Congenital Abnormalities
  • Hypospadias
  • Congenital megaprepuce
  • Histology
03

Who can participate

Ages eligible
1 Month to 10 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Male patients diagnosed with congenital megaprepuce and hypospadias scheduled for surgical correction.

Inclusion criteria

  • Male patients scheduled for correction of congenital megaprepuce
  • Male patients scheduled for correction of hypospadias
  • Male patients scheduled for circumcision for non-medical reasons.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of hypospadias correction.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Congenital Megaprepuce

    Congenital Megaprepuce Hematoxylin-eosin and smooth muscle actin markers

    Diagnostic Test: Hematoxylin-eosin and smooth muscle actin markers

  • Hypospadias

    Hypospadias Hematoxylin-eosin and smooth muscle actin markers

    Diagnostic Test: Hematoxylin-eosin and smooth muscle actin markers

  • Control

    Circumcision for non-medical reasons. Hematoxylin-eosin and smooth muscle actin markers

    Diagnostic Test: Hematoxylin-eosin and smooth muscle actin markers

Interventions

  • Diagnostic testHematoxylin-eosin and smooth muscle actin markers

    The foreskin arrives oriented in a single piece in formol to the unit of pathology, and in the pathology unit, they must: 1. Measure the length, width and thickness of the specimen. The specimen should include skin and mucosa with the underlying areolar tissue. 2. Examine the surfaces of the sample searching lesions, and describe them in size, appearance (warty, papillary, ulcerated), depth of invasion, and distance from the nearest cutting edge, if they are present.

05

What researchers measure

Primary outcomes

  1. Differences in the distribution of the smooth Muscle In Dartos

    Smooth Muscle Fibers

    Time frame: 1 year

  2. Describe the pattern of smooth muscle in patients with megaprepuce

    Smooth Muscle Fibers

    Time frame: 1 year

Secondary outcomes

  1. Describe the pattern of smooth muscle in patients with hypospadias

    Smooth Muscle Fibers

    Time frame: 1 year

06

Study locations

1 site
  • Luis Gabriel Villarraga
    Bogotá, 110231, Colombia
07

References and documents

Publications

  • Ruiz E, Vagni R, Apostolo C, Moldes J, Rodriguez H, Ormaechea M, Giuseppucci C, de Badiola F, Bortagaray J, Perea C. Simplified surgical approach to congenital megaprepuce: fixing, unfurling and tailoring revisited. J Urol. 2011 Jun;185(6 Suppl):2487-90. doi: 10.1016/j.juro.2011.01.015. Epub 2011 Apr 27. PubMed 21527191 ↗
  • Summerton DJ, McNally J, Denny AJ, Malone PS. Congenital megaprepuce: an emerging condition--how to recognize and treat it. BJU Int. 2000 Sep;86(4):519-22. doi: 10.1046/j.1464-410x.2000.00509.x. PubMed 10971284 ↗
  • Rod J, Desmonts A, Petit T, Ravasse P. Congenital megaprepuce: a 12-year experience (52 cases) of this specific form of buried penis. J Pediatr Urol. 2013 Dec;9(6 Pt A):784-8. doi: 10.1016/j.jpurol.2012.10.010. Epub 2012 Oct 30. PubMed 23116700 ↗
  • Alexander A, Lorenzo AJ, Salle JL, Rode H. The Ventral V-plasty: a simple procedure for the reconstruction of a congenital megaprepuce. J Pediatr Surg. 2010 Aug;45(8):1741-7. doi: 10.1016/j.jpedsurg.2010.03.033. PubMed 20713233 ↗
  • Borsellino A, Spagnoli A, Vallasciani S, Martini L, Ferro F. Surgical approach to concealed penis: technical refinements and outcome. Urology. 2007 Jun;69(6):1195-8. doi: 10.1016/j.urology.2007.01.065. PubMed 17572214 ↗
  • Spinoit AF, Van Praet C, Groen LA, Van Laecke E, Praet M, Hoebeke P. Congenital penile pathology is associated with abnormal development of the dartos muscle: a prospective study of primary penile surgery at a tertiary referral center. J Urol. 2015 May;193(5):1620-4. doi: 10.1016/j.juro.2014.10.090. Epub 2014 Oct 23. PubMed 25444989 ↗
  • Cimador M, Catalano P, Ortolano R, Giuffre M. The inconspicuous penis in children. Nat Rev Urol. 2015 Apr;12(4):205-15. doi: 10.1038/nrurol.2015.49. Epub 2015 Apr 7. PubMed 25850928 ↗
  • Maizels M, Zaontz M, Donovan J, Bushnick PN, Firlit CF. Surgical correction of the buried penis: description of a classification system and a technique to correct the disorder. J Urol. 1986 Jul;136(1 Pt 2):268-71. doi: 10.1016/s0022-5347(17)44837-3. PubMed 2873259 ↗
  • Crawford BS. Buried penis. Br J Plast Surg. 1977 Jan;30(1):96-9. doi: 10.1016/s0007-1226(77)90046-7. PubMed 836989 ↗
  • Shenoy MU, Rance CH. Surgical correction of congenital megaprepuce. Pediatr Surg Int. 1999;15(8):593-4. doi: 10.1007/s003830050683. PubMed 10631746 ↗
  • Hadidi AT. Buried penis: classification surgical approach. J Pediatr Surg. 2014 Feb;49(2):374-9. doi: 10.1016/j.jpedsurg.2013.09.066. Epub 2013 Nov 7. PubMed 24528990 ↗
  • Baskin LS, Himes K, Colborn T. Hypospadias and endocrine disruption: is there a connection? Environ Health Perspect. 2001 Nov;109(11):1175-83. doi: 10.1289/ehp.011091175. PubMed 11713004 ↗
  • Baskin LS, Ebbers MB. Hypospadias: anatomy, etiology, and technique. J Pediatr Surg. 2006 Mar;41(3):463-72. doi: 10.1016/j.jpedsurg.2005.11.059. PubMed 16516617 ↗
  • Fernandez N, Lorenzo A, Bagli D, Zarante I. Altitude as a risk factor for the development of hypospadias. Geographical cluster distribution analysis in South America. J Pediatr Urol. 2016 Oct;12(5):307.e1-307.e5. doi: 10.1016/j.jpurol.2016.03.015. Epub 2016 Apr 22. PubMed 27267992 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03295175
Lead sponsor
Hospital Universitario San Ignacio
Responsible party
Sponsor
First posted
Sep 27, 2017
Start date
Sep 21, 2017
Primary completion
Mar 12, 2024
Completion
Mar 12, 2024
Last update
Mar 13, 2024

Study contacts

Jose N Fernandez, MD
principal investigator · H

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion